Result Update Q4, FY 14

Target - Rs. 715



Reco: Buy

Atul came up with decent set of numbers and surpasses our estimates both top line and bottom line. In Q4,14 top line grew by 32% (YoY) while on a full year basis top line grew by 18%. We have incorporated FY 16 estimates and change our target price from Rs. 548 to Rs. 715.

## Observations:

- ~ Atul Posted double digit growth of 32% in Q4,14 YoY on a consolidated level mainly because of lower base of Q4,13.
- ~ EBIDTA margin continue expanded from 12.3% to 14.8% in Q4,14 because of high absorption of fixed component.
- ~ Both segment life science and Performance chemical performed well grew by 6% and 43% respectively. EBIDTA also grew by 40% in Q4,14.
- ~ Company has indicated that Capex for FY 15 will be around Rs. 1000 million and focus on improvement in margin and working capital.
- ~ China is imposing strict regulation for chemical companies so as to protect environment and which is providing benefit not only atul but also entire chemical industries.
- $^{\sim}$  Later or sooner Indian government will also impose restriction to protect environment. Company has taken measure to make it zero discharge units.

 $^{\sim}$  International business contributes approx. 50% of total revenue which is actually helping company to reduce dependence on domestic growth.


Figures are in Rs. Cr.

| Quarter Result            | 201403 | 201303 | % Change | 201312 | % Change |
|---------------------------|--------|--------|----------|--------|----------|
| Net Sales                 | 648.07 | 491    | 32%      | 575.77 | 13%      |
| Other Operating Income    | 19.92  | 11.99  | 66%      | 16.22  | 23%      |
| Other Income              | 0.34   | 5.13   | -93%     | 19.87  | -98%     |
| Total Income              | 668.33 | 508.12 | 32%      | 611.86 | 9%       |
| Total Expenditure         | 568.05 | 455.86 | 25%      | 505.47 | 12%      |
| PBIDT                     | 100.28 | 52.26  | 92%      | 106.39 | -6%      |
| Interest                  | 9.25   | 7.36   | 26%      | 7.38   | 25%      |
| PBDT                      | 91.03  | 44.9   | 103%     | 99.01  | -8%      |
| Depreciation              | 17.3   | 13.02  | 33%      | 11.94  | 45%      |
| Tax                       | 23.07  | 6      | 285%     | 15     | 54%      |
| Deferred Tax              | -0.9   | 4.44   | -120%    | 6.83   | -113%    |
| Reported Profit After Tax | 51.56  | 21.44  | 140%     | 65.24  | -21%     |
| Reference Items           |        |        |          |        |          |
| EBIDTA Margin %           | 15.0%  | 10.3%  | 472      | 17.4%  | -240     |
| PAT Margin %              | 7.7%   | 4.2%   | 350      | 10.7%  | -300     |
|                           |        |        |          |        |          |

5 May 2014

Result Update Q4, FY 14

**Target – Rs. 715** 



| Income Statement | FY 12a  | FY 13a  | FY 14a  | FY 15e  | FY 16e  |
|------------------|---------|---------|---------|---------|---------|
| Net Revenue      | 1,792.4 | 2,042.9 | 2,457.8 | 2,797.9 | 3,189.7 |
| EBIDTA           | 205.0   | 252.5   | 363.7   | 414.1   | 472.0   |
| EBIDTA Margin %  | 11.4%   | 12.4%   | 14.8%   | 14.8%   | 14.8%   |
| Depreication     | 44.02   | 51.37   | 58.26   | 68.10   | 78.34   |
| EBIT             | 161.0   | 201.1   | 305.5   | 346.0   | 393.7   |
| Interest         | 43.31   | 34.88   | 33.44   | 30.23   | 30      |
| EBT              | 117.7   | 166.2   | 272.0   | 315.7   | 363.7   |
| Other Income     | 12.4    | 20.2    | 36.3    | 23.0    | 26.5    |
| EBT              | 130.1   | 186.4   | 308.3   | 338.7   | 390.2   |
| Tax              | 39.5    | 66.5    | 88.4    | 97.0    | 111.7   |
| MI & Associates  | -4.4    | -8.2    | -0.3    | -0.3    | -0.3    |
| PAT              | 90.6    | 119.9   | 220.0   | 241.7   | 278.4   |

We increased our target price from Rs. 548 to Rs. 715 based on FY 16e earning. We continue to value the company based on DCF valuation and increased our target price from Rs. 548 to Rs. 715 based on improvement in ROIC (Post tax) and improvement in margins profile of company. At CMP stock is quoting at EV/EBIDTA of 4.95x and 4.34x for FY 15e and FY 16e.



5 May 2014

Result Update Q4, FY 14

**Target – Rs. 715** 



## Disclaimer

This report has been issued by Anand Rathi Share & Stock Brokers Ltd.(ARSSBL), which is regulated by SEBI. The information herein was obtained from various sources; we do not guarantee its accuracy or completeness. Neither the information nor any opinion expressed constitutes an offer, or an invitation to make an offer, to buy or sell any securities, options, future or other derivatives related to such securities ("related investment"). ARSSBL and its affiliated may trade for their own accounts as market maker/jobber and /or arbitrageur in any securities of this issuer(s) or in related investments, and may be on the opposite side of public orders. ARS, its affiliates, directors, officers, and employees may have a long or short position in any securities of this issuer(s) or in related investment banking or other business from, any entity mentioned in this report. This research report is prepared for private circulation. It does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. Investors should seek financial situation and the particular needs of any specific investing in any securities or investment strategies discussed or recommended in this report and should understand that statements regarding future prospects may not be realized. Investors should note that income from such securities, if any, may fluctuate and that each security's price or value may rise or fall. Past performance is not necessarily a guide to future performance. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related investment mentioned in this report.